Squire Patton Boggs has advised international medical devices company Biocomposites on the acquisition of the remaining shares in Laboratorios SL S.A. and Synergie Ingénierie Médicale S.A.R.L. manufacturer and distributor of the SYNICEMTM and Subiton product ranges. This acquisition follows Biocomposites’ initial majority investment in the SYNICEMTM and Subiton products in 2022, a transaction that was also advised on by Squire Patton Boggs.
The team advising Biocomposites was led by Corporate partner David Milne and senior associate Joshua Astill-Headley.
Biocomposites engineers, manufactures, and markets products for use in infection management in bone and soft tissue. Based in Keele in the UK, it has global operations across Europe, US, Argentina, Canada, China, and India. Biocomposites is a world leader in the development of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in over one million procedures per annum and sold in more than 100 countries around the world.
Simon G. Greenhalgh, Group Chief Financial Officer at Biocomposites, said: “This was an important acquisition for our company, building on the success of our initial investment in the SYNICEM and Subiton products and our strategic aim to drive further product innovation in bone and soft tissue infections.
“Squire Patton Boggs provided expert advice to us at every stage of this journey, with first-class support from David, Josh and the team. Their in-depth knowledge of our business, coupled with a practical and very commercial approach to getting the deal done, was impressive – particularly since we were working under the pressure of a challenging timescale. We are grateful of their efforts and continued support.”